Results 11 to 20 of about 89,818 (264)
Indian Journal of Dermatology, Venereology and Leprology, 2023 The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway is a key regulatory signaling system for cellular proliferation, differentiation, and apoptosis. In addition, JAK signaling pathway plays critical roles in orchestrating immune response through its interactions with the cytokine receptors and the transcriptions ...
Siba P, Raychaudhuri +1 more
openaire +2 more sources
JAK inhibitors in rheumatology
Immunological Medicine, 2023 Janus kinase inhibitors (JAKis) are a group of drugs with a different mechanism of action from biologics and are most rapidly uptaken in the rheumatology field. JAK is a protein kinase activated in the cytoplasm by multiple cytokines and hormones involved in inflammatory pathology. The expression of JAK has been observed in various diseases, indicating
Kunihiro Yamaoka, Kenji Oku
openaire +3 more sources
Journal of Allergy and Clinical Immunology, 2021 Asthma is an inflammatory disease of the airways characterized by intermittent episodes of wheezing, chest tightness, and cough. Many of the inflammatory pathways implicated in asthma involve cytokines and growth factors that activate Janus kinases (JAKs).
Steve N, Georas +3 more
openaire +3 more sources
The safety of JAK-1 inhibitors [PDF]
Rheumatology, 2021 Abstract As efficacy and safety data emerge, differences between JAK inhibitor subclasses are appearing. JAK1 selective drugs, upadacitinib and filgotinib, have broadly come with the same overarching safety recommendations as other immunosuppressive drugs for RA: caution is needed regarding infection risk; monitoring for laboratory ...
Benjamin Clarke +4 more
openaire +3 more sources
The JAK-STAT Pathway and the JAK Inhibitors [PDF]
Journal of Clinical Research in Dermatology, 2020 Dozens of cytokines that bind Type I and Type II receptors use the Janus Kinases (JAK) and the Signal Transducer and Activator of Transcription (STAT) proteins pathway for intracellular signaling, orchestrating hematopoiesis, inducing inflammation, and controlling the immune response.
Ana Paula Galli Sanchez +2 more
openaire +1 more source
JAK inhibitors in autoinflammation [PDF]
Journal of Clinical Investigation, 2018 Interferonopathies are a subset of autoinflammatory disorders with a prominent type I IFN gene signature. Treatment of these patients has been challenging, given the lack of response to common autoinflammatory therapeutics including IL-1 and TNF blockade.
Hal M, Hoffman, Lori, Broderick
openaire +2 more sources
Immunological Medicine, 2023 Among various tyrosine kinases, a family of Janus kinases (JAK) has been elucidated as key players in signal transduction from vital cytokine receptors, such as interleukins and interferons. Indeed, recent rapid progress in JAK inhibitors in addition to biological agents provided therapeutic options for various diseases, including immune-mediated ...
openaire +3 more sources
HemaSphere, 2023 The oral activin A receptor type I, Janus kinase 1 (JAK1), and JAK2 inhibitor momelotinib demonstrated symptom, spleen, and anemia benefits in intermediate- and high-risk myelofibrosis (MF).
Jean-Jacques Kiladjian +19 more
doaj +1 more source
Methotrexate Is a JAK/STAT Pathway Inhibitor. [PDF]
PLoS ONE, 2015 The JAK/STAT pathway transduces signals from multiple cytokines and controls haematopoiesis, immunity and inflammation. In addition, pathological activation is seen in multiple malignancies including the myeloproliferative neoplasms (MPNs).
Sally Thomas +5 more
doaj +1 more source
JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL. [PDF]
PLoS ONE, 2015 Constitutive activation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) axis is fundamental to the molecular pathogenesis of a host of hematological disorders, including acute leukemias and myeloproliferative neoplasms ...
Jun Guo +5 more
doaj +1 more source